Abide Therapeutics to Present at EUFEMED Annual Meeting on ABX-1431 Clinical Program

SAN DIEGO, May 17, 2017 /PRNewswire/ — Abide Therapeutics, a developer of innovative pharmaceuticals, announced today that new preclinical and clinical data on ABX-1431, an investigational monoacylglycerol lipase (MGLL) inhibitor, will be presented in a poster session at the European Federation for Exploratory Medicines Development Annual Meeting 2017 (EUFEMED), taking place in London, May 18-19, 2017. ABX-1431 is a first-in-mechanism, …

Abide Therapeutics Announces Dosing of First Subject in fMRI Imaging Study to Investigate Brain Activity Patterns Associated with ABX-1431

SAN DIEGO, May 10, 2017 /PRNewswire/ — Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of dosing in a Phase 1 study using functional magnetic resonance imaging (fMRI) to evaluate patterns of neural activity in the brain associated with oral administration of ABX-1431, a first-in-class investigational monoacylglycerol lipase (MGLL) inhibitor, which modulates the activity of the endocannabinoid neurotransmitter …

Abide Therapeutics Announces Dosing of First Patient In Phase 1b Study of ABX-1431 in Tourette Syndrome and Collaboration with Tourette Association of America

SAN DIEGO, April 18, 2017 /PRNewswire/ — Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of dosing in a Phase 1b study to evaluate the effects of ABX-1431, a first-in-class investigational monoacylglycerol lipase (MGLL) inhibitor in patients with Tourette Syndrome (TS). TS is a neurodevelopmental disorder characterized by sudden, involuntary movements and/or sounds called tics. Additionally, Abide has …

Abide Therapeutics Announces First Patient Dosed in Phase 1b Study to Assess the Effect of ABX-1431 in Patients with Functional Dyspepsia

SAN DIEGO, December 14, 2016 /PRNewswire/ — Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of dosing in a Phase 1b study to evaluate the effects of ABX-1431, a first-in-class investigational monoacylglycerol lipase (MGLL) inhibitor, on gastric accommodation in patients with functional dyspepsia (FD), a gastrointestinal disorder characterized by altered gut motility and pain. “MGLL inhibitors have the …

Jason Clapper on “In vivo characterization of a selective monoacylglycerol lipase inhibitor ABD-1970 in rodents and activity in models of pain”

San Diego, Nov. 15, 2016 Abstract Monoacylglycerol lipase (MGLL) is the primary regulator of 2-arachidonoylglycerol (2-AG) an endogenous ligand of the cannabinoid (CB) receptors CB1 and CB2. Selective blockade of MGLL inhibits the hydrolytic degradation of 2-AG resulting in elevated 2-AG levels in the CNS and periphery, and CB1/2-dependent anti-nociceptive and anti-inflammatory effects. In the rodent brain and select peripheral …

Jackie Blankman at Society for Neuroscience “In vitro characterization of a selective monoacylglycerol lipase inhibitor ABD-1970 in human systems”

San Diego, November 15, 2016 Abstract Monoacylglycerol lipase (MGLL) is a serine hydrolase enzyme that converts monoacylglycerols into fatty acids and glycerol. The MGLL substrate 2-arachidonoylglycerol (2-AG) is an endogenous ligand of the cannabinoid receptors CB1 and CB2, which are the molecular targets of the psychoactive component of Cannabis sativa, Δ9tetrahydrocannabinol (THC). Inhibition or genetic inactivation of MGLL results in …

Abide Therapeutics Announces Celgene Option Exercise to Develop ABX-1431, an Investigational Endocannabinoid System Modulator for Patients with Neurological Diseases

SAN DIEGO, September 29, 2016 Abide Therapeutics announced today that Celgene has exercised its option to obtain ex-US rights to Abide’s first-in-class endocannabinoid system modulator, ABX-1431, for the potential treatment of neurological diseases. Celgene will be responsible for development costs for all indications from Phase 2 clinical trials and beyond. Abide retains US rights and will conduct a number of …

Abide Therapeutics Announces First Subject Dosed In PET Occupancy Study with [18F]ABX-1488, a Proprietary Human Monoacylglycerol Lipase (MGLL)-Specific PET Ligand

SAN DIEGO, May 10, 2016 /PRNewswire/ — Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of enrollment and dosing in a Phase 1 PET occupancy study with ABX-1431, a first-in-class investigational monoacylglycerol lipase (MGLL) inhibitor, and [18F]ABX-1488, a human MGLL-specific PET ligand. ABX-1431, which was discovered with Abide’s proprietary technology platform targeting serine hydrolases, has successfully completed dosing …

Abide Therapeutics Appoints Richard N. Kender to Board of Directors

SAN DIEGO, January (19), 2016 /PRNewswire/ — Abide Therapeutics announced today the appointment of Richard N. Kender to its Board of Directors. Kender is a consultant to biotechnology companies in the areas of partnerships and licensing and mergers and acquisitions. He was previously Senior Vice President of Business Development and Corporate Licensing at Merck & Co., Inc. During his career …

Abide’s Co-founders and Board Members Elected to the National Academy of Inventors

SAN DIEGO, Jan 15, 2016– Abide Therapeutics congratulates the company’s co-founders and Scientific Advisory Board members Drs. Benjamin Cravatt and Dale Boger, and Board of Directors member Dr. Paul Schimmel, on their election to the National Academy of Inventors. Election to the National Academy of Inventors recognizes exceptional contributions to the creation or facilitation of inventions that have made an …